🇺🇸 Aliskiren/HCTZ in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 11

Most-reported reactions

1. Oedema Peripheral — 2 reports (18.18%)
2. Alkalosis Hypochloraemic — 1 report (9.09%)
3. Asthenia — 1 report (9.09%)
4. Atrioventricular Block First Degree — 1 report (9.09%)
5. Bacterial Sepsis — 1 report (9.09%)
6. Blood Creatinine Increased — 1 report (9.09%)
7. Bradycardia — 1 report (9.09%)
8. Cardiac Failure — 1 report (9.09%)
9. Chest Pain — 1 report (9.09%)
10. Clavicle Fracture — 1 report (9.09%)

Source database →

Frequently asked questions

Is Aliskiren/HCTZ approved in United States?

Aliskiren/HCTZ does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Aliskiren/HCTZ in United States?

Novartis is the originator. The local marketing authorisation holder may differ — check the official source linked above.